# A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C

Study · id `cardio:ct-nct04998981` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04998981](<https://clinicaltrials.gov/study/NCT04998981>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04998981

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.

## Technical summary

Registry record NCT04998981. Randomized; quadruple masking; primary purpose treatment. Start 2021-09-17 (actual); primary completion 2023-02-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 353 participants (enrolled count; ClinicalTrials.gov record NCT04998981, source copy `cardio:ctgov-nct04998981-2025-05-23`, retrieved 2026-10-31)
- Started: 2021-09-17 (actual) (ClinicalTrials.gov record NCT04998981, source copy `cardio:ctgov-nct04998981-2025-05-23`, retrieved 2026-10-31)
- Primary completion: 2023-02-02 (actual) (ClinicalTrials.gov record NCT04998981, source copy `cardio:ctgov-nct04998981-2025-05-23`, retrieved 2026-10-31)
- Completion: 2023-02-02 (actual) (ClinicalTrials.gov record NCT04998981, source copy `cardio:ctgov-nct04998981-2025-05-23`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04998981, source copy `cardio:ctgov-nct04998981-2025-05-23`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04998981-2025-05-23`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C
- Condition: Hyperlipidemia
- Intervention (Drug): K-877 0.1 mg tablet
- Intervention (Drug): Fenofibrate 200 mg capsule
- Intervention (Drug): Placebo tablet
- Intervention (Drug): Placebo capsule
- Intervention (Drug): K-877 0.1 mg tablet
- Intervention (Drug): Placebo tablet
- Lead sponsor: Kowa Company, Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Kowa Company, Ltd. (`cardio:org-kowa-company-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial (`cardio:pubmed-39098034`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 977c9a5b6de6a485a94d4a9213f9d2572a2f9eac55873b9472ebb11c63dfb6f9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
